Atai Life Sciences N : Company Presentation June 2024

Healingmental health disorders so that everyone everywhere can live a more fulfilled life.

Company Overview - June 2024

02

Disclaimer

All references in this presentation to "we", "us", "our", "atai", or the

"Company" refer to ATAI Life Sciences N.V. and its consolidated

subsidiaries, unless the context otherwise requires. This presentation

contains forward-looking statements within the meaning of the private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered under by the safe harbor provisions for forward- looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended." All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, industry dynamics, business strategy and plans and our objectives for future operations, are forward- looking statements. These statements represent our opinions, expectations, beliefs, intentions, estimates or strategies regarding the future, which may not be realized. In some cases, you can identify forward- looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions that are intended to identify forward-looking statements. Forward-looking statements are based largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the important factors described in the section titled "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), as updated by our subsequent filings with the SEC, that may cause our actual results, performance or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements. Moreover, we operate in a very competitive and rapidly

changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our businessor the extent towhich any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements.

The forward-looking statements included in this presentation are made only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor our advisors nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Neither we nor our advisors undertake any obligation to update any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as may be required by law. You should read this presentation with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information

released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions made by usupon reviewing such data, and our experience in, and knowledgeof, such industry and markets, which we believe to be reasonable. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate or of any individual competitor and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by us. Industry publications, research, surveys and studies generally state that the information they contain has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this presentation.

This presentation contains excerpts of testimonials from individuals who have been treated with compounds or derivatives of the compounds underlying our product candidates in the context of third-party studies or otherwise that are solely intended to be illustrative and not representative of the potential for beneficial results of such compounds. Our product candidates are in preclinical or clinical stages of development and none of our product candidates have been approved by the FDA or any other regulatory agency.

Any trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.

Highlights

03

atai Life Sciences: Healing mental health disorders so that everyone everywhere can live a more fulfilled life

1	Mental health disorders are one of the largest global health burdens; in 2019, 1 in every 8 people, or approx. 1
billion people around the world, were living with a mental disorder.1

2	atai's objective is to enable mental health patients to achieve clinically meaningful and sustained behavioral
change through developing innovative, rapid-acting and durable therapeutics.

3	Eight clinical-stage psychedelic and non-psychedelic programs and strategic investments, each with a
robust package of prior clinical evidence.

4	Validated operating model and ability to capture value: IPO of COMPASS Pathways in 2020 and
licensing deal between Otsuka and atai subsidiary Perception Neuroscience in 2021.

5	Cash, marketable securities, and committed term loan funding expected to provide runway into 2026.2

1. World Health Organization
2. Committed term loan funding includes $45M of additional capital that can be drawn not subject to milestones under the facility with Hercules Capital; marketable securities includes money market funds, U.S. Treasury securities, commercial paper, corporate notes/bonds, U.S. government agencies securities, and public equities

Drug Development Programs and Strategic Investments

Our strategy will be delivered through a robust portfolio of psychedelic and non- psychedelic drug development programs and strategic investments

Programs / Investments		Primary Indication	Preclin		Phase 1		Phase 2		Phase 3

PSYCHEDELIC PROGRAMS & STRATEGIC INVESTMENTS

COMP3601 / Psilocybin	Treatment-Resistant Depression
BPL-0032 /5-MEO-DMT	Treatment-Resistant Depression
VLS-01 / DMT	Treatment-Resistant Depression
ELE-1012 / Psilocin	Major Depressive Disorder
IBX-210 / Ibogaine	Opioid Use Disorder
EMP-01 /R-MDMA	Undisclosed
EGX-A & EGX-B / Novel 5-HT2A Receptor Agonists	Undisclosed

NON-PSYCHEDELICPROGRAMS

RL-007 /Pro-cognitive neuromodulator3	Cognitive Impairment Associated
with Schizophrenia
GRX-917 / Deuterated etifoxine		Generalized Anxiety Disorder
1 Strategic Investment in Compass Pathways	3 RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts		Strategic Investment
2 Strategic Investment in Beckley PsyTech

Upcoming Catalysts

05

We expect to deliver several meaningful R&D milestones anticipated across our key programs and strategic investments through 2024 and 20251

Achieved and expected milestones1

(2024-25)

H1'24

o VLSPh 1b-01first participant dosed

o BPL-003

Ph 2a OL (TRD) Part 1 data

1. ELE-101
   Ph 1/2a OL (MDD) initial data

o COMP360Ph 2 (PTSD) data (Spring '24)

1. All dates provided are as estimated

H2'24

1. VLS-01
   Ph 1b topline data

1. BPL-003
   Ph 2a OL (AUD) data (mid'24)

1. COMP360
   Ph 3 (TRD) Pivotal Trial 1 topline data

1. BPL-003
   Ph 2b (TRD) patient recruitment completed

1. IBX-210
   Ph 1/2a initiation

1. VLS-01
   Ph 2 initiation (around YE'24)

2025

1. RL-007
   Ph 2b (CIAS) topline data (mid'25)

1. COMP360
   Ph 3 (TRD) Pivotal Trial 2 topline data (mid'25)

06

Programs in

Depression

BPL-003,VLS-01, COMP360, ELE-101

atai's Depression Portfolio Comparison

07

A diverse portfolio of differentiated psychedelic assets to address the heterogeneity of patients who suffer from depression

Route of

Receptor binding affinity

Rapid Onset

Appr.

Associated

Primary

of Treatment

Duration

Program

Compound

Indication

Administration

(5-HT2A :5-HT1A )1

Effect

in clinic

BPL-003 5-MeO-DMT

TRD

Intranasal

0.01

~2h

VLS-01	DMT	TRD	Oral	3.4	~2h
transmucosal film

COMP360 Psilocybin2

TRD

Oral

2.0

~6h

ELE-101

Psilocin

MDD

Intravenous

2.0

~2h

1 Besnard et al. 2012 // 2 Psilocybin is not present in the body in meaningful concentrations after oral consumption // Abbreviations: TRD = Treatment Resistant Depression; MDD = Major Depressive Disorder

Commercial Positioning

08

atai's focus is on psychedelics with the potential to leverage the 2-hour interventional psychiatry treatment paradigm successfully established by Spravato®

Anticipated hours in-clinic1

Anticipated in-clinic time based on duration of subjective effects1

(in hours) Illustrative

12

~8 to 12

8		~6 to 8
	~2 to 6*	~6
4
~2	~2

0
Spravato® BPL-003	Multi-dose Psilocybin MDMA	LSD
	/ VLS-01	5-MeO- + analogs
	/ ELE-101	DMT

1

2

3

Key Takeaways

BPL-003,VLS-01 and ELE-101 have the potential in depression to offer a predictable, single-dose model administered within the 2-hour in-clinictreatment paradigm established by Spravato®

We anticipate this facilitates more scalable adoption and allows clinics to accommodate a greater number of patients daily, compared to psychedelics with longer duration subjective effects

This may ultimately drive improved patient convenience and treatment access in the >4,000 certified delivery clinics2 for Spravato® with proven reimbursement and logistics pathways

1. Subject to further validation through future clinical studies and real-world evidence
2. https://www.spravatohcp.com/#find-a-center

• If multi-dose required

09

BPL-003

(5-MeO-DMT) for TRD & AUD

Strategic Investment into Beckley Psytech

BPL-003: Phase 1 Results

10

Beckley Psytech's BPL-003 had a favorable safety profile and was well tolerated in the Phase 1 SAD study, with no observed serious or severe adverse events

BPL-003 Phase 1 Treatment-Emergent Adverse Events (TEAEs)1

	Placebo				BPL-003 dose (N=31)				Total
		1 mg	2.5 mg	4mg	6 mg	8 mg	10mg	12 mg
	N=13			N=44
		N=4	N=4	N=4	N=4	N=5	N=5	N=5
Any TEAEs	2		1	1	4	3	4	2	4		21
Nasal discomfort				1	2	2	2		3		10
Nausea					2	1	2	1	1		7
Vomiting					2		1		2		5
Headache	1				1		2				4
Administration							1	1			2
site pain
Chest discomfort							1				1
Dizziness								1			1
Pyrexia	1										1
Gastroenteritis			1								1
Back pain					1						1
Hypoesthesia						1					1
Limb discomfort						1					1
Tremor							1				1
Lacrimation									1		1
Increased
Restlessness									1		1

1 n = number of subjects reporting at least one TEAE in that category, % - rounded proportion of cohort total

Key Takeaways

There were no severe or serious adverse events

1 observed, and 89.5% TEAEs were mild and

10.5% were moderate in severity.

Most common TEAEs (>10%) were nasal

2 discomfort, nausea, vomiting, and headache. TEAEs did not appear to correlate with dose.

There were no clinically significant findings for

3 laboratory parameters, vital signs, ECGs or physical examinations.

Blood pressure and heart rate increases were

4 transient and resolved within 90 min without intervention. None were considered clinically significant.

5	Results from the C-SSRS showed participants
experienced no increase in suicidal thoughts,
	intentions or behavior.